A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
Zinc-finger domains are intrinsically cell-permeable and capable of mediating protein delivery into a broad range of mammalian cell types. Here, a detailed step-by-step protocol for implementing zinc-finger technology for intracellular protein delivery is presented.
Due to their modularity and ability to be reprogrammed to recognize a wide range of DNA sequences, Cys2-His2 zinc-finger DNA-binding domains have emerged as useful tools for targeted genome engineering. Like many other DNA-binding proteins, zinc-fingers also possess the innate ability to cross cell membranes. We recently demonstrated that this intrinsic cell-permeability could be leveraged for intracellular protein delivery. Genetic fusion of zinc-finger motifs leads to efficient transport of protein and enzyme cargo into a broad range of mammalian cell types. Unlike other protein transduction technologies, delivery via zinc-finger domains does not inhibit enzyme activity and leads to high levels of cytosolic delivery. Here a detailed step-by-step protocol is presented for the implementation of zinc-finger technology for protein delivery into mammalian cells. Key steps for achieving high levels of intracellular zinc-finger-mediated delivery are highlighted and strategies for maximizing the performance of this system are discussed.
Highly efficient and versatile protein delivery strategies are critical for many basic research and therapeutic applications. The direct delivery of purified proteins into cells represents one of the safest and easiest methods for achieving this.1,2 Unlike strategies that rely on gene expression from nucleic acids,3-5 protein delivery poses no risk of insertional mutagenesis, is independent of the cellular transcription/translation machinery and allows for an immediate effect. However, the lack of simple and generalizable methods for endowing cell-penetrating activity onto proteins routinely confounds their direct entry into cells. Current methods for facilitating intracellular protein delivery are based on the use of naturally occurring6-8 or designed cell-penetrating peptides,9-12 supercharged transduction domains,13,14 nanoparticles15 and liposomes,16 virus-like particles17,18 and polymeric microsphere materials.19 Unfortunately, many of these approaches are hampered by low cellular uptake rates,20,21 poor stability,22 inadvertent cell-type specificity,23 low endosomal escape properties24 and toxicity.25 In addition, many protein transduction technologies reduce the bioactivity of the delivered proteins.14
Our laboratory previously demonstrated that zinc-finger nuclease (ZFN) proteins — chimeric restriction endonucleases consisting of a programmable Cys2-His2 zinc-finger DNA-binding protein and the cleavage domain of the FokI restriction endonuclease26-28 — are inherently cell-permeable.29 This surprising cell-penetrating activity was shown to be an intrinsic property of the custom-designed zinc-finger domain, a DNA-binding platform that has emerged as a powerful tool for targeted genome engineering,30-32 and considered to be the result of the constellation of six positively charged residues on the protein surface. Indeed, several DNA-binding proteins, including c-Jun and N-DEK have been shown to possess an innate capacity to cross cell membranes.33 More recently, our laboratory expanded on these results and demonstrated that the cell-penetrating activity of zinc-finger (ZiF) domains could be leveraged for intracellular protein delivery. Genetic fusion of either one- or two-finger ZiF domains to specific protein cargo led to uptake efficiencies that exceeded many conventional cell-penetrating peptide delivery systems.34 Most notably, ZiF-mediated delivery did not compromise the activity of fused enzymatic cargo and facilitated high levels of cytosolic delivery. Collectively, these findings demonstrate the potential of the ZiF domain for facilitating the efficient and facile delivery of proteins, and potentially more diverse types of macromolecules, into cells.
Here, a detailed step-by-step protocol on how to implement ZiF technology for protein delivery in mammalian cells is presented. We previously constructed a suite of one-, two-, three-, four-, five- and six-finger ZiF domains that lack the ability to bind DNA, due to substitution of each of the α-helical DNA-binding residues, but are capable of delivering proteins into cells34 (Figure 1). The production and transduction of Emerald GFP (EmGFP) into HeLa cells using a two-finger ZiF domain is described. This protocol is extensible to almost any protein capable of soluble expression in Escherichia coli and nearly any mammalian cell type. Expected results are provided and strategies for maximizing the performance of this system are also discussed.
Access restricted. Please log in or start a trial to view this content.
1. Cloning
2. Expression and Purification
3. Protein Storage
4. Protein Transduction
Access restricted. Please log in or start a trial to view this content.
Two-finger ZiF-EmGFP fusion proteins can be expressed in E. coli with >95% homogeneity and high yields (>25 mg/ml) (Figure 2). In general, one- and two-finger ZiF fusion proteins can be produced in quantities nearly identical to those of wild-type unmodified protein. However, in some contexts, five- and six-finger ZiF fusion proteins are unable to be produced in yields high enough for downstream applications.
Direct application of two-finger ZiF-EmGFP protein ...
Access restricted. Please log in or start a trial to view this content.
Here, a step-by-step protocol for protein delivery using cell-permeable zinc-finger (ZiF) domains is presented. The ZiF domain does not reduce the activity of fused enzymatic cargo34; allows for the production and purification of proteins in yields nearly identical to those observed with unmodified protein; and can transport proteins and enzymes into a wide range of cell types with efficiencies that exceed traditional cell-penetrating peptide or protein transduction domain systems. Together, these findings ind...
Access restricted. Please log in or start a trial to view this content.
The authors have nothing to disclose.
This work was supported by the National Institutes of Health (DP1CA174426 to Carlos F. Barbas) and ShanghaiTech University, Shanghai, China (to J.L). Molecular graphics were generated using PyMol.
Access restricted. Please log in or start a trial to view this content.
Name | Company | Catalog Number | Comments |
XmaI | New England Biolabs | R0180L | |
SacI | New England Biolabs | R0156L | |
Expand High Fidelity PCR system | Roche | 11759078001 | |
dNTPs | New England Biolabs | N0446S | |
4%-20% Tris-Glycine Mini protein gels, 1.5 mm, 10 wells | Life Technologies | EC6028BOX | |
2x Laemmli Sample Buffer | BioRad | 161-0737 | |
T4 DNA Ligase | Life Technologies | 15224-017 | |
BL21 (DE3) Competent E. coli | New England Biolabs | C2527I | |
IPTG | Thermo Scientific | R0391 | |
Zinc Chloride | Sigma-Aldrich | 208086-5G | |
Kanamycin Sulfate | Fisher Scientific | BP906-5 | |
Glucose | Sigma-Aldrich | G8270-100G | |
Tris Base | Fisher Scientific | BP152-25 | |
Sodium Chloride | Sigma-Aldrich | S9888-25G | |
DTT | Fisher Scientific | PR-V3151 | |
PMSF | Thermo Scientific | 36978 | |
Ni-NTA Agarose Resin | QIAGEN | 30210 | |
Glycerol | Sigma-Aldrich | G5516-500ML | |
Imidazole | Sigma-Aldrich | I5513-25G | |
Amicon Ultra-15 Centrifugal Filter Units | EMO Millipore | UFC900324 | |
DMEM | Life Technologies | 11966-025 | |
Fetal Bovine Serum | Life Technologies | 10437-028 | |
Antibiotic-Antimycotic | Life Technologies | 15240-062 | |
24-Well Flat Bottom Plate | Sigma-Aldrich | CLS3527-100EA | |
Poly-Lysine | Sigma-Aldrich | P7280 | |
DPBS, No Calcium, No Magnesium | Life Technologies | 21600010 | |
Heparan Sulfate | Sigma-Aldrich | H4777 | |
Trypsin | Life Technologies | 25300054 | |
HeLa cells | ATCC | CCL-2 | |
Nano Drop ND-1000 spectrophotometer | Thermo Fisher Scientific | ||
QIAquick PCR Purification Kit | QIAGEN | 28104 | |
QIAquick Gel Extraction Kit | QIAGEN | 28704 |
Access restricted. Please log in or start a trial to view this content.
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved